Company profilePharmaceutical#159 of 1,318 in Pakistan✓ No DRAP alerts

Raazee Therapeutics (Pvt Ltd.

Pharmaceutical company · 108 brands · 99 molecules

Ranked #34 of 50 companies in Antimalarials

108 registered products 46 pharmaceutical brands 99 distinct molecules 0 DRAP alerts

Company overview

108
registered products
46
pharmaceutical brands
99
distinct molecules
7
therapeutic classes
0
DRAP alerts

Raazee Therapeutics (Pvt Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 108 product registrations across 99 distinct molecules. It is the 159th largest registrant in Pakistan by product count, and ranks 34th of 50 in Antimalarials. Its portfolio is concentrated in Antimalarials and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Raazee

85 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Other Beta-Lactam, Cephalosporins & Penems 2
Angiotensin-Ii Antagonists, Combinations 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

81
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202681

Top molecules by brand count

Therapeutic classes

Antimalarials · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Neuro · 1Appetite Stimulant · 1Anti-Infectives · 1Angiotensin-Ii Antagonists, Combinations · 1Antianemic, Iron Preparations · 1

Conditions treated

Migraine/Appetite Stimulant · 1Fungal Infection · 1Bladder & Prostate Disorder · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official120 products · Rs 6.2 – Rs 2,126.71
Servaid3 products · Rs 125 – Rs 320.1
Median across source: Rs 303.87

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

MEDIATE PHARMACEUTICALS (PVT) LTD holds 84 molecules not in this portfolio
AcyclovirAlendronateAmoxicillinAmpicillinAmpicillin BaseAnastrozole
SCOTMANN PHARMACEUTICALS holds 69 molecules not in this portfolio
AmilorideAmmonium ChlorideAmoxicillin BaseAnastrazoleApixabanBenzoyl Peroxide
HIGH - Q INTERNATIONAL holds 106 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAnastrozoleAprepitantArachis OilAtorvastatin

Get the full profile for Raazee

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.